P669: ANALYSIS OF FACTORS INFLUENCING THE DECISION TO STOP TKI TREATMENT IN CML PATIENTS IN DEEP MOLECULAR RESPONSE
Semerad, Lukas, Žáčková, Daniela, Belohlavkova, Petra, Voglova, Jaroslava, Žák, Pavel, Faber, Edgar, Papajik, Tomas, Skoumalova, Ivana, Karas, Michal, Jindra, Pavel, Klamová, Hana, Salek, Cyril, Srbová, Dana, Zizkova, Hana, Stejskal, Lukas, Cerna, Olga, Cmunt, Eduard, Cicatkova, Petra, Kvetkova, Anezka, Hornak, Tomas, Jeziskova, Ivana, Jurcek, Tomas, Weinbergerová, Barbora, Prochazkova, Jirina, Machova Polakova, Katerina, Svobodnik, Adam, Stepanova, Radka, Mayer, Jiri
Published in HemaSphere (08.08.2023)
Published in HemaSphere (08.08.2023)
Get full text
Journal Article
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF
Žáčková, Daniela, Semerád, Lukáš, Faber, Edgar, Klamová, Hana, Stejskal, Lukáš, Bělohlávková, Petra, Karas, Michal, Cmunt, Eduard, Černá, Olga, Procházková, Jiřina, Čičátková, Petra, Kvetková, Anežka, Horňák, Tomáš, Skoumalová, Ivana, Srbová, Dana, Šálek, Cyril, Buffa, David, Voglová, Jaroslava, Jurček, Tomáš, Folta, Adam, Ježíšková, Ivana, Žižková, Hana, Machová Poláková, Kateřina, Papajík, Tomáš, Žák, Pavel, Jindra, Pavel, Svobodník, Adam, Štěpánová, Radka, Mayer, Jiří
Published in Leukemia (01.04.2024)
Published in Leukemia (01.04.2024)
Get full text
Journal Article
Real World Population- Based Data from Nationwide Registry Support the Existence of Accelerated Phase in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients Even in Tyrosine Kinase Inhibitors (TKIs) Era
Hornak, Tomas, Mayer, Jiri, Cicatkova, Petra, Semerad, Lukas, Kvetkova, Anezka, Klamova, Hana, Faber, Edgar, Belohlavkova, Petra, Karas, Michal, Stejskal, Lukas, Cmunt, Eduard, Cerna, Olga, Srbova, Dana, Zizkova, Hana, Vrablova, Lucia, Skoumalova, Ivana, Voglova, Jaroslava, Jurkova, Tereza, Chrapava, Marika, Jurcek, Tomas, Jeziskova, Ivana, Jarosova, Marie, Machova Polakova, Katerina, Papajik, Tomas, Zak, Pavel, Jindra, Pavel, Zackova, Daniela
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article
De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors
Hornak, Tomas, Mayer, Jiri, Cicatkova, Petra, Semerad, Lukas, Kvetkova, Anezka, Klamova, Hana, Faber, Edgar, Belohlavkova, Petra, Karas, Michal, Stejskal, Lukas, Cmunt, Eduard, Cerna, Olga, Srbova, Dana, Zizkova, Hana, Vrablova, Lucia, Skoumalova, Ivana, Voglova, Jaroslava, Jurkova, Tereza, Chrapava, Marika, Jurcek, Tomas, Jeziskova, Ivana, Jarosova, Marie, Machova Polakova, Katerina, Papajik, Tomas, Zak, Pavel, Jindra, Pavel, Zackova, Daniela
Published in American journal of hematology (01.04.2024)
Published in American journal of hematology (01.04.2024)
Get full text
Journal Article
Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice
Zackova, Daniela, Klamova, Hana, Belohlavkova, Petra, Stejskal, Lukas, Necasova, Tereza, Semerad, Lukas, Weinbergerova, Barbora, Srbova, Dana, Voglova, Jaroslava, Cicatkova, Petra, Sustkova, Zuzana, Hornak, Tomas, Baranova, Jana, Prochazkova, Jirina, Mayer, Jiri
Published in Leukemia & lymphoma (02.01.2021)
Published in Leukemia & lymphoma (02.01.2021)
Get full text
Journal Article
Propensity Score Matching Comparing Asciminib Versus Ponatinib in Chronic Myeloid Leukemia Patients Who Failed Prior Tyrosine Kinase Inhibitor Therapy
Perusini, Maria Agustina, Kockerols, Camille, Žáčková, Daniela, Nicolini, Franck E., Castagnetti, Fausto, Pavlovsky, Carolina, Breccia, Massimo, Rea, Delphine, Fava, Carmen, Savoie, Mary Lynn, Bouvier, Christophe, Čičátková, Petra, Bollard, Julien, Linn, Swe Mar, Gupta, Gopila, Scalzulli, Emilia, Mayer, Jiří, Westerweel, Peter E, Kim, Dennis Dong Hwan
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article
Half: A Prospective Multi-Centre Phase II Clinical Trial Evaluating the Efficacy and Safety of Tyrosine Kinase Inhibitors' Discontinuation after Two-Step Dose Reduction in Patients with Chronic Myeloid Leukemia in Deep Molecular Remission
Žácková, Daniela, Faber, Edgar, Stejskal, Lukáš, Karas, Michal, Bělohlávková, Petra, Klamová, Hana, Černá, Olga, Cmunt, Eduard, Čičátková, Petra, Semerád, Lukáš, Horňák, Tomáš, Kvetková, Anežka, Procházková, Jiřina, Rychlíčková, Jitka, Štěpánová, Radka, Svobodník, Adam, Machová Poláková, Kateřina, Ježíšková, Ivana, Jurček, Tomáš, Borský, Marek, Wiewiorka, Ondřej, Demlová, Regina, Mayer, Jiří
Published in Blood (23.11.2021)
Published in Blood (23.11.2021)
Get full text
Journal Article
What is the optimal dose of tyrosine kinase inhibitors in chronic myeloid leukaemia?
Žáčková, Daniela, Čičátková, Petra, Kvetková, Anežka, Horňák, Tomáš, Semerád, Lukáš, Mayer, Jiří
Published in Transfuze a hematologie dnes (12.03.2021)
Published in Transfuze a hematologie dnes (12.03.2021)
Get full text
Journal Article
Vascular adverse events in chronic myeloid leukaemia patients during tyrosine kinase inhibitor therapy in daily clinical practice – analysis from the INFINITY database
Čičátková, Petra, Žáčková, Daniela, Horňák, Tomáš, Klamová, Hana, Bělohlávková, Petra, Stejskal, Lukáš, Křístková, Zlatuše, Baranová, Jana, Kvetková, Anežka, Semerád, Lukáš, Procházková, Jiřina, Mayer, Jiří
Published in Transfuze a hematologie dnes (15.03.2023)
Published in Transfuze a hematologie dnes (15.03.2023)
Get full text
Journal Article